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Male breast cancer accounts for about one percent of all breast can-
cer cases and is more common among individuals with a family his-
tory of breast cancer.
In particular, BRCA-2 mutation represents one of the most 
clearly established risk factors for male breast cancer.1,2 According 
to previous literature, 14%-16% of men with carcinoma of the breast 
are known to be BRCA-2 mutation carriers.3-5 On these bases, inter-
national guidelines recommend that all males diagnosed with breast 
cancer should undergo genetic testing. On the other hand, BRCA-1 
mutation has a much lower incidence in male population.
In the present paper, we describe the uncommon case of a male 
bilateral risk-reducing mastectomy in a BRCA-2 male carrier.
A 37-year-old man with no relevant clinical history, highly ed-
ucated and working in medical setting, with a family history of 
breast cancer, came to our Family Cancer Clinic to undergo genetic 
counseling. During the first evaluation, the family tree was drawn 
(Figure 1) and the family was judged worthy of BRCA genetic test-
ing. Particularly, patient's father, diagnosed with breast cancer 
when 71 years old, performed genetic testing and resulted BRCA-2 
carrier. We proposed to the patient an instrumental and clinical 
surveillance program for the risk of breast cancer, but also for the 
possible association with prostatic and gastro-intestinal tumors. 
The execution of a baseline mammary ultrasound did not reveal ret-
ro-areolar alterations nor the presence of nodules or gynecomastia. 
Since the patient was strongly affected by family experience, and by 
the progression of father's illness, he strongly requested a bilateral 
risk-reducing mastectomy. Although a guideline-based prevention 
program was planned with monthly self-examination, clinical check 
and breast ultrasound every 6 months, and tests for prostate cancer 
screening, the patient remained firm on the request for surgery. 
We proposed a psychological intervention, which he performed to-
gether with his wife. At first, his wife was skeptical about the surgi-
cal option, but finally she supported his choice. The couple was very 
collaborative and cohesive.
The patient showed a very proactive behavior, and he strongly 
motivated his choice underling the suffering of his father, the sense 
of responsibility upon his children, and the desire to avoid breast 
cancer. After this careful psychological counseling, the multi-disci-
plinary team concluded to proceed with surgery.
A bilateral simple mastectomy with nipple-areola complex re-
moval was performed under general anesthesia. The postoperative 
course was regular. Final histology did not show the presence of any 
pathological tissue.
Clinical and instrumental follow-up is negative after 5 years. 
Nevertheless, no further follow-up will be available because the pa-
tient died by committing suicide.
Although male carriers of the BRCA-2 mutations have a markedly 
increased risk of breast cancer, the estimated lifetime risk in the general 
population of men is very low (0.1%).1 Hence, this condition remains 
rare and no specific guideline suggests considering risk-reducing mas-
tectomy as an option for males carrying the BRCA mutation.
Previous studies showed that, in cohorts of BRCA-2 women, 
breast cancer-specific survival resulted similar in patients that un-
derwent surveillance and in patients who underwent risk-reduction 
surgery.6 Nonetheless, neither family history nor further risk fac-
tors were considered in the data recording. Beside the absence of 
overall and breast cancer-specific survival, the key role of tailored 
counseling is widespread. Factors like age at the time of diagnosis, 
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cancerophobia, low adherence to surveillance programs, or signif-
icant family history may sometimes influence the choice between 
surveillance and risk-reducing surgery.
In literature, male prophylactic mastectomy is described only 
in sporadic cases and always performed in men with BRCA mu-
tation with a contralateral breast cancer diagnosis.7,8 Despite the 
absence of a survival benefit,9 the use of contralateral prophylactic 
mastectomy for men who received a diagnosis of unilateral breast 
cancer has substantially increased over time.8 The same trend is 
recognized in women population.10 This may suggest that patient's 
personal choice is becoming more and more important in genetic 
counseling.
Health care professionals have the role to educate patients on 
benefits, risks, and implications of surveillance programs versus 
risk-reducing strategies, and to flank the patient to reach shared de-
cisions. This case may suggest that we need to tailor counseling and 
decision-making process for males carrying BRCA mutation and take 
into consideration risk-reduction surgery when wished and strongly 
motivated by the consultant or in the presence of multiple risk fac-
tors in addition to gene mutation.
In our experience, the involvement of family members in the 
counseling process is also greatly important.
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